Is VEEV a good stock to buy? We came across a bullish thesis on Veeva Systems Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on VEEV. Veeva Systems Inc.’s share was trading at $167.95 as of April 17th. VEEV’s trailing and forward P/E were 30.87 and 18.94, respectively according to Yahoo Finance.
Wichy/Shutterstock.com
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. VEEV operates at the center of a durable, non-cyclical digital transformation within the global life sciences industry, positioning itself as the core operating system for critical workflows spanning clinical development, regulatory compliance, and commercial operations.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The company benefits from strong secular tailwinds, including rising pharmaceutical R&D spending driven by aging populations, increasing pressure to accelerate drug development timelines, and rapid adoption of AI-driven solutions, all of which reinforce demand for Veeva’s integrated cloud platform.
Despite a temporary slowdown in FY2024, Veeva has re-accelerated growth, delivering 16.2% revenue expansion in FY2025 with improving revenue quality as subscription services now comprise roughly 84% of total revenue. The SaaS model continues to drive meaningful operating leverage, with significant margin expansion expected as the company transitions away from Salesforce, eliminating approximately $80 million in annual royalty payments by 2030.
Veeva’s dominant industry position, including approximately 80% market share in life sciences CRM and deep penetration across top pharmaceutical companies, creates high switching costs and a powerful competitive moat reinforced by regulatory complexity. Financially, the company maintains a fortress balance sheet with over $6.5 billion in net cash and strong free cash flow generation, enabling continued investment and strategic flexibility.
While near-term concerns around CRM competition and client renewals have pressured valuation, this appears largely sentiment-driven rather than fundamental. With multiple catalysts, including CRM migration success, AI monetization, and continued R&D platform expansion, Veeva presents a compelling long-term opportunity with favorable risk-reward skew and potential for sustained compounding growth.
Previously, we covered a bullish thesis on Veeva Systems Inc. (VEEV) by Francesco Ferrari in March 2025, which highlighted the company’s resilient high-ARR model, strong margins, and consistent cash flow generation. VEEV’s stock price has depreciated by approximately 29.91% since our coverage. Danny Green shares a similar view but emphasizes secular tailwinds, AI-led growth, and margin expansion from Salesforce independence.
Veeva Systems Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 75 hedge fund portfolios held VEEV at the end of the fourth quarter which was 57 in the previous quarter. While we acknowledge the risk and potential of VEEV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VEEV and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
